As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The SYNERGY Division of Hetero Healthcare focuses on providing therapeutic solutions across cardiovascular and metabolic healthcare, supporting the effective management of chronic and lifestyle-related conditions.
Its portfolio addresses key areas such as hypertension, dyslipidaemia, diabetes, cardiovascular risk management, and associated metabolic disorders, offering therapeutic options that support comprehensive and long-term patient care.
Backed by Hetero Healthcare’s commitment to quality, accessibility, and patient-centric care, SYNERGY strives to provide dependable therapies that support effective clinical management and better patient outcomes.
View by-
